Zenas BioPharma Secures Up to $300 Million Funding for Obexelimab Development and Potential IgG4-RD Launch

Zenas BioPharma and Royalty Pharma have entered into a funding agreement for up to $300 million. The initial $75 million will fund the potential US commercial launch of obexelimab for IgG4-Related Disease. Additional $150 million is associated with the upcoming results of the obexelimab Phase 3 INDIGO trial and FDA approval for IgG4-Related Disease treatment. This agreement will support obexelimab development and a potential IgG4-RD commercial launch in the first half of 2027.